Melanoma & Skin Cancer | Specialty

Duration of Immunotherapy in Melanoma

December 16th 2015

Sequencing of Checkpoint Agents in Melanoma

December 16th 2015

Use of Immunotherapy Agents in Melanoma Treatment

December 16th 2015

Role of Surgery in the Management of Advanced Melanoma

December 16th 2015

Radiation Therapy and Abscopal Effect in Melanoma Treatment

December 16th 2015

Practical Application of T-VEC in Melanoma Treatment

December 16th 2015

Systemic Therapy with T-VEC in Advanced Melanoma

December 16th 2015

Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma

December 14th 2015

Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.

Ashani Weeraratna on Aging and Melanoma

December 14th 2015

Ashani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ß-catenin signaling in melanoma.

James Allison on Exciting Immunotherapy Advancements in Melanoma

December 14th 2015

James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.

Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab Combination

December 1st 2015

Tara C. Mitchell, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.

James Allison on the Future of Checkpoint Inhibitors in Melanoma

November 30th 2015

James Allison, PhD, discusses the rapidly expanding field of immunotherapy in melanoma.

UC Davis Meets NCI-Designation With Great Responsibility

November 30th 2015

Conference Highlights, Three FDA Approvals, and More

November 30th 2015

FDA Issues Complete Response Letter for Nivolumab in BRAF-Mutant Melanoma

November 27th 2015

The FDA has requested additional data for the use of single-agent nivolumab in previously untreated patients with BRAF V600 mutation-positive advanced melanoma.

Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma

November 27th 2015

Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.

Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in Melanoma

November 25th 2015

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

European Commission Approves Vemurafenib/Cobimetinib Combo for Melanoma

November 25th 2015

The European Commission has approved the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) as a treatment for patients with BRAF-positive metastatic or unresectable melanoma.

Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma

November 25th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib plus trametinib versus vemurafenib plus cobimetinib.

FDA Approves Frontline Nivolumab for Advanced Melanoma

November 24th 2015

The FDA has expanded the approval for single-agent nivolumab (Opdivo) to include the frontline treatment of patients with BRAF wild-type advanced melanoma.